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ABSTRACT
Objective To estimate the test accuracy of faecal 
calprotectin (FC) for inflammatory bowel disease (IBD) in 
the primary care setting using routine electronic health 
records.
Design Retrospective cohort test accuracy study.
Setting UK primary care.
Participants 5970 patients (≥18 years) without a previous 
IBD diagnosis and with a first FC test between 1 January 
2006 and 31 December 2016. We excluded multiple tests 
and tests without numeric results in units of µg/g.
Intervention FC testing for the diagnosis of IBD. Disease 
status was confirmed by a recorded diagnostic code and/
or a drug code of an IBD- specific medication at three time 
points after the FC test date.
Main outcome measures Sensitivity, specificity, and 
positive and negative predictive values for the differential 
of IBD versus non- IBD and IBD versus irritable bowel 
syndrome (IBS) at the 50 and 100 µg/g thresholds.
Results 5970 patients met the inclusion criteria and 
had at least 6 months of follow- up data after FC testing. 
1897 had an IBS diagnosis, 208 had an IBD diagnosis, 
31 had a colorectal cancer diagnosis, 80 had more than 
one diagnosis and 3754 had no subsequent diagnosis. 
Sensitivity, specificity, and positive and negative predictive 
values were 92.9% (88.6% to 95.6%), 61.5% (60.2% 
to 62.7%), 8.1% (7.1% to 9.2%) and 99.6% (99.3% to 
99.7%), respectively, at the threshold of 50 µg/g. Raising 
the threshold to 100 µg/g missed less than 7% additional 
IBD cases. Longer follow- up had no effect on test 
accuracy. Overall, uncertainty was greater for specificity 
than sensitivity. General practitioners’ (GPs’) referral 
decisions did not follow the anticipated clinical pathways 
in national guidance.
Conclusions GPs can be confident in excluding IBD on the 
basis of a negative FC test in a population with low pretest 
risk but should interpret a positive test with caution. The 
applicability of national guidance to general practice needs 
to be improved.
INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic, 
progressive disorder caused by inflammation 
of the gastrointestinal tract. The prevalence 
of IBD is rising worldwide, with the highest 
reported prevalence values in North America 
(568 per 100 000 persons) and Europe (827 
per 100 000 persons).1 UK prevalence esti-
mates were 970/100 000 in 2017.2 It often 
presents with non- specific symptoms such 
as abdominal pain and diarrhoea, making it 
difficult to differentiate from irritable bowel 
syndrome (IBS), which is far more prevalent 
in the primary care setting. This also affects 
the numbers and composition of referrals 
to secondary care, with a higher proportion 
of patients being diagnosed in secondary 
care with IBS than is desirable. It is against 
this background that the non- invasive faecal 
calprotectin (FC) test has been introduced as 
a test for IBD in primary care in the UK. FC 
is a small calcium- binding protein of the S100 
family which is predominantly derived from 
neutrophils during an immune response. It 
is associated with inflammation and can be 
Strengths and limitations of this study
 ► The sample size in our study is likely to be larger 
than the usual cross- sectional studies used to eval-
uate a test, which is useful for inflammatory bowel 
disease (IBD) which has a low prevalence.
 ► We applied strict eligibility criteria to ensure the 
reliability of reported test accuracy measures and 
explored the effects of different follow- up times on 
the definition of IBD.
 ► We used a very comprehensive and sensitive list of 
Read codes and drug codes (48 codes) for the iden-
tification of IBD.
 ► The exclusion of close to half of the faecal calpro-
tectin tests without a numerical test result raises 
concerns over the generalisability of the findings; 
however, findings are in line with published 
estimates.
 ► A coded IBD diagnosis or prescription is a proxy 
reference standard for a composite of different ref-
erence tests used in clinical practice reflecting a 
pragmatic approach to test accuracy.
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quantified in stool samples.3 Therefore, it is more specific 
than serum inflammatory markers in the detection of 
gastrointestinal inflammation.3
The FC test is recommended by gastroenterological 
societies across the globe for its usefulness in the diag-
nosis of IBD.4–7 However, there is no clear guidance on 
which settings it is considered appropriate. The National 
Institute for Health and Care Excellence (NICE) recom-
mends the use of FC testing in UK primary care for the 
differential diagnosis of IBD and IBS when a referral is 
being considered and colorectal cancer (CRC) is not 
suspected.8 A study of routine data from an American 
health plans database of FC testing for chronic gastroin-
testinal symptoms in primary care suggests that it is used 
in routine general practice in at least one other country.9 
The NICE recommendations were based on an evalua-
tion of secondary care test accuracy studies and assump-
tions that referral decisions would follow FC test results. 
This resulted in a slow uptake and inconsistent use of FC 
testing in primary care.10 While primary care studies exist, 
we still lack compelling evidence on the test accuracy of 
FC testing in primary care for the detection of IBD. This 
is because the primary care evidence is based on small, 
heterogeneous studies that vary in clinical questions, FC 
thresholds and definitions of disease.11 They report a 
range of sensitivities and specificities with wide CIs and 
leave uncertainty over which threshold (50 or 100 µg/g) 
should be adopted in primary care. To determine the 
utility of FC testing in primary care, a pragmatic study 
is required that both captures the differential diagnosis 
between IBD and IBS and has a patient population that is 
representative of primary care.
Thus, our primary aim was to determine the diagnostic 
value of FC for IBD in primary care by estimating the 
sensitivity, specificity and predictive values for two thresh-
olds using routine UK primary care data from the IQVIA 
Medical Research Database (IMRD)- UK.
METHODS
Data source
We undertook a test accuracy study of FC testing for IBD 
using data from the IMRD- UK (formerly known as The 
Health Improvement Network (THIN)). IMRD- UK is a 
UK longitudinal primary care database of over 14 million 
patients from more than 670 general practitioner (GP) 
practices covering about 6% of the UK population in 
2015.12 It has been found to be broadly representative of 
the UK population.13 Patients’ medical diagnoses, symp-
toms, laboratory tests, referrals and prescriptions are 
available as clinical codes (eg, Read codes).
Study design and population
This retrospective cohort study included patients (≥18 
years) who had no previous IBD diagnosis and who 
had their first FC test between 1 January 2006 and 31 
December 2016. Eligible patients had also contributed at 
least 12 months of data to IMRD- UK before their study 
start date. FC tests were identified using all six Read codes 
available to GPs to record an FC test.
Classification of FC test results
FC tests with a numeric result of >50 and >100 µg/g were 
considered positive in two separate analyses. We included 
a post hoc analysis at the threshold of 250 µg/g in light of 
the latest recommendations of a pathway using two cut- 
offs.10 14 FC tests without results, with invalid results, qual-
itative results only, missing units of measurement or units 
of measurement other than µg/g were excluded from the 
analysis.
Definition of disease
IBD was defined as a record of a Read code for ulcerative 
colitis, Crohn’s disease, indeterminate colitis or micro-
scopic colitis. Read code lists were adapted from those 
used in previous literature.15–17 This was supplemented 
with the record of an IBD- specific prescription to increase 
the sensitivity of the algorithm. IBS and CRC were defined 
by any clinical code that suggested a definitive diagnosis. 
Abdominal symptoms were not considered sufficiently 
specific for an IBS diagnosis. We excluded benign and 
precancerous stages of CRC. In three different analyses a 
diagnosis was considered when it was recorded within 6, 
12 or 24 months of the FC test date to explore the impact 
of late diagnoses in patients with sufficient follow- up after 
FC testing. We considered the following symptoms to 
assess eligibility for testing: diarrhoea, abdominal pain, 
constipation, bloating and change in bowel habit. See 
online supplemental table 1 for the final code lists of 
these variables.
Definition of referral
Our definition of IBD was based on the assumption that 
IBD diagnoses were only recorded following confirma-
tory testing in secondary care. We explored this assump-
tion by investigating FC testing in the referred population 
only. We considered a referral to any specialty that was 
made within 6 weeks of the index FC test to be a referral 
in response to FC testing.
Statistical analysis
Data management and analysis were undertaken in R 
V.3.6.1 (Vienna, Austria).18 The main outcomes of the 
analysis were sensitivity, specificity, and positive (PPV) 
and negative predictive values (NPV). These were calcu-
lated in two ways: (1) Patients with a recorded IBD diag-
nosis were classed as disease positive and those without an 
IBD diagnosis (IBS, CRC, alternative diagnosis, no diag-
nosis) were classed as disease negative. (2) Patients with 
an IBD diagnosis were classed as disease positive and only 
those with an IBS diagnosis were classed as disease nega-
tive. CIs for proportions were computed using the Wilson 
method.19 We used the Koopman method to compute CIs 
for likelihood ratios.20
We used receiver operating characteristic (ROC) 
curves to display the accuracy of the FC test at test positive 
thresholds between 33 and 300 µg/g. This allowed the 
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inclusion of results recorded as >300 and <33 µg/g. ROC 
curves for different follow- up times were compared using 
Venkatraman’s method for two unpaired ROC curves in 
the absence of a feasible paired comparison because data 
were of different sizes.21
We computed proportions of patients referred with a 
true positive (TP), false positive (FP), false negative (FN) 
and true negative (TN) FC test result in order to investi-
gate the effect the FC test results have on patient manage-
ment. If the test results had no impact on referral, the 
proportions across groups were expected to be similar. 
If GPs act on the test result (refer positives and manage 
negatives), the proportion of patients referred with TP 
and FP results was expected to be (1) close to one, (2) 
equal and (3) greater than those for FN and TN results 
(both close to 0). The proportions of referred patients 
were compared using the two proportions z- test.
Sensitivity analyses were conducted in order to inves-
tigate the effects different assumptions have on the test 
accuracy estimates. Specifically, we investigated including 
all units of measurements; including qualitative results 
in addition to quantitative results; defining IBD by Read 
code only; and confining analyses to only those patients 
referred to secondary care. We also explored the effects 
of excluding patients not eligible for the FC testing as 
according to national guidance (patients with an age >50 
years or symptoms for <6 weeks).
Patient involvement
A patient advisory group was actively involved in the 
funding application for the project. The group provided 
a patient perspective in the design of the study and the 
interpretation of study findings.
RESULTS
A total of 17 466 first time FC tests in a total of 6 965 853 
adult primary care patients were recorded in the study 
period, and 5970 were included in the analysis (figure 1). 
Of these, 1987 (32%) had an IBS diagnosis, 208 (3.5%) an 
IBD diagnosis, 31 (0.5%) a CRC diagnosis, 78 (1%) had 
an IBD and an IBS diagnosis, 2 had an IBD and a CRC 
diagnosis, and 3754 (63%) had no diagnosis recorded 
at any time after the FC test (see online supplemental 
table 2). Of the 5970 patients, 1434 (24%) had an IBS 
diagnosis recorded at the time of FC testing. The propor-
tion of patients with an IBD or IBS diagnosis was slightly 
higher in the included group than in the excluded group 
(see online supplemental table 2).
Test accuracy of FC testing for IBD
In 5970 patients with at least 6 months of follow- up avail-
able after the FC test date (figure 1), the sensitivity of the 
FC test in detecting IBD at a threshold of 50 µg/g was 
92.9% (95% CI 88.6% to 95.6%). Specificity was 61.5% 
(95% CI 60.2% to 62.7%). The positive predictive value 
(PPV) was low at 8.1% (95% CI 7.1% to 9.2%), while the 
NPV was high (99.6% (95% CI 99.3% to 99.7%)) at an 
IBD prevalence of 3.5% (table 1). The positive likelihood 
ratio was 2.41 (95% CI 2.28 to 2.52), which suggests that 
FC testing only slightly increases the probability of IBD. 
The negative likelihood ratio was 0.12 (95% CI 0.07 to 
0.19), which suggests strong evidence to rule out IBD. 
The inclusion of IBD cases that were recorded up to 
12 (analysis of 4793 FC tested patients) and 24 months 
(2662 patients) following an FC test had no significant 
effect on the measures of test accuracy (table 1). Small 
changes observed in the point estimates may be due to 
the different population size and the different make- up of 
the study population. Eighty- seven per cent (2096/2414) 
of patients with a positive FC test result had no recorded 
diagnosis of IBD, IBS or CRC 6 months after the FC test 
date. Of these, 501 had a previous diagnosis of IBS or 
CRC. At the end of the study period, there were still 1470 
(61%) patients with a positive test but without a diagnosis 
of interest. These patients could either have had a missed 
diagnosis, no diagnosis or an alternative diagnosis, which 
was not included in our study. For patients with a nega-
tive FC test, 92% (3277/3556) had none of the three 
Figure 1 Flow diagram of inclusion criteria of faecal 
calprotectin (FC) tested patients into test accuracy study. 
*Results not coded invalid or indeterminate in IQVIA Medical 
Research Database (IMRD)- UK. †Fifteen different units of 
measurements were used to record FC levels. µg/g is the 
most commonly used in publications and laboratories. 
††FC level of >30µg/g ambiguous at 50µg/g and 100µg/g 
thresholds
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diagnoses recorded at 6 months and 64% (2284/3556) 
had none of the three diagnoses at any time after FC 
testing.
The ROC curves in figure 2 describe the sensitivity and 
false positive rate (1- specificity) for the three different 
follow- up times at additional thresholds. The 50 µg/g 
threshold prioritises sensitivity over specificity in all three 
analyses. There was generally good agreement between 
the three curves (E=0.0016758, p=0.406 comparing 6 
months with 24 months of follow- up).
Increasing the FC threshold
Figure 3 shows that an increase in the threshold from 50 
to 100 µg/g affects the specificity more than the sensi-
tivity (online supplemental table 3). Increasing the 
threshold reduces the number of false positives by 875 
at the expense of missing an additional 14 cases of IBD 
in a population of 5970 tested patients, suggesting that 
the proportion of IBD cases missed due to this threshold 
difference is less than 7% (14/210). IBD cases missed 
were 31% (65/210) when we changed the threshold to 
250 µg/g (online supplemental table 3).
Restricting the population to patients with IBD or IBS
Changing the definition of the non- diseased group from 
non- IBD to IBS reduced the number of false positives and 
true negatives. Consequently, the point estimates of spec-
ificity and PPV increased by about 10% and 60%, respec-
tively, at the 50 µg/g threshold (table 2). However, the 
dataset was small (576 vs 5970) and, thus, increases the 
potential for sampling error. This may limit the clinical 
applicability of the findings.
Sensitivity analyses
Overall, the sensitivity analyses revealed greater uncer-
tainty in the estimate of specificity than sensitivity 
(table 3). Inclusion of numerical results reported in other 
units of measurement had no impact on estimates of test 
accuracy. The majority of qualitative results were positive 
at the 50 µg/g threshold, which may indicate preferential 
recording of positive test results using qualitative codes. In 
this sensitivity analysis, the specificity was lower due to the 
great number of false positives. Only 569 patients tested 
had symptoms recorded that met the national guidance 
eligibility criteria. The recording of symptoms was not 
associated with the FC test result. Test accuracy measures 
in this subset did not differ from those estimated using 
the full dataset. Reclassifying 79 patients as IBD negative 
Table 1 Test accuracy measures of faecal calprotectin (FC) testing at a threshold of 50 µg/g









6 months 5970 195 2219 15 3541 92.9 (88.6 to 95.6) 61.5 (60.2 to 62.7) 8.1 (7.1 to 9.2) 99.6 (99.3 to 99.7)
12 months 4793 198 1790 16 2789 92.5 (88.2 to 95.3) 60.9 (59.5 to 62.3) 10 (8.7 to 11.4) 99.4 (99.1 to 99.6)
24 months 2662 129 1067 11 1455 92.1 (86.5 to 95.6) 57.7 (55.8 to 59.6) 10.8 (9.2 to 12.7) 99.2 (98.7 to 99.6)
*Time following FC testing to consider a record of inflammatory bowel disease.
FN, false negatives; FP, false positives; N, sample size; NPV, negative predictive value; PPV, positive predictive value; TN, true negatives; TP, 
true positives.
Figure 2 Receiver operating characteristic curve of 
sensitivity and false positive rate (1- specificity) for thresholds 
of 33–300 µg/g for the clinical question inflammatory bowel 
disease (IBD) versus non- IBD for tests with at least 6 months 
(n=5970), 12 months (n=4793) and 24 months (n=2662) 
follow- up available after the faecal calprotectin test date.
Figure 3 Sensitivity and specificity at thresholds of 33–
300 µg/g for inflammatory bowel disease (IBD) versus non- 
IBD and IBD recorded within 6 months following the faecal 
calprotectin (FC) test date (n=5970).
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who had an IBD diagnosis affirmed by an IBD- specific 
drug code only (Read code negative) had no impact on 
the test accuracy estimates. Finally, of the 5970 FC tests, 
52% resulted in a referral. The specificity of FC testing 
in this subgroup was lower because of the non- referral of 
mainly true negatives.
Impact of test results on referral decisions
Table 4 shows the classification of all included patients 
and those referred within 6 weeks of their FC test 
according to their test result and disease status. If GPs 
referred patients based on positive FC test results, they 
would have referred 2414 out of 5970 (40.4%) included 
patients. This would have detected 195 out of 210 (92.9%) 
IBD cases. However, 6 weeks after FC testing, 3078 out of 
5970 (51.6%) patients were referred, including 1610 out 
of 3556 (45.3%) FC negative patients and only 149 out 
of 210 (71.0%) IBD cases. Therefore, the test result was 
not the single determining factor for or against a timely 
referral. Patients with true positive and false negative FC 
test results were equally likely to be referred for further 
tests (70.8% vs 73.3%, z=2, p=0.8371). Both groups were 
referred more frequently than patients with false positive 
(59.9%) (z=3, p=0.0028) or true negative results (45.3%) 
(z=7, p<0.0001). This may suggest that GPs used alterna-
tive cues (in the history, examination or other tests) which 
raised their suspicion of IBD. Overall, GP assessment plus 
FC testing may be worse than FC testing alone. Compared 
with FC testing alone, the number of patients with a true 
positive result was lower for GP assessment plus testing 
because GPs did not refer all test positive patients within 
6 weeks. GPs referred some patients with a false negative 
FC test result on the test, but not enough to make up for 
not referring patients with true positive results on the test.
DISCUSSION
Study findings
After excluding FC tests with no result or an ambiguous 
result, the sensitivity of the FC test in detecting IBD at 
the 50 µg/g threshold was high (92.9% (95% CI 88.6% 
to 95.6%)) but the specificity was modest (61.5% (95% 
60.2% to 62.7%)). Moreover, the sensitivity analyses 
demonstrated greater uncertainty in our estimates of the 
specificity. The high false positive rate may be irrelevant 
Table 2 Test accuracy measures for faecal calprotectin (FC) testing at the threshold of 50 µg/g for the detection of IBD 
recorded within 6 months of FC testing considering two different definitions of the non- diseased group











5970 195 2219 15 3541 92.9 (88.6 to 95.6) 61.5 (60.2 to 62.7) 8.1 (7.1 to 9.2) 99.6 (99.3 to 99.7)
IBD vs IBS 576 195 104 15 262 92.9 (88.6 to 95.6) 71.6 (66.8 to 76) 65.2 (59.7 to 70.4) 94.6 (91.3 to 96.7)
FN, false negative; FP, false positive; IBD, inflammatory bowel disease; IBS, irritable bowel syndrome; N, sample size; NPV, negative 
predictive value; PPV, positive predictive value; TN, true negative; TP, true positive.
Table 3 Sensitivity analyses compared with primary analysis of FC testing for IBD vs non- IBD at a threshold of 50 µg/g with 
IBD recorded within 6 months









Primary analysis 5970 195 2219 15 3541 92.9 (88.6 to 95.6) 61.5 (60.2 to 62.7) 8.1 (7.1 to 9.2) 99.6 (99.3 to 99.7)
FC tests with any 
unit
6758 220 2481 17 4040 92.8 (88.8 to 95.5) 62 (60.8 to 63.1) 8.1 (7.2 to 9.2) 99.6 (99.3 to 99.7)
Qualitative results 
included*




569 20 194 1 354 95.2 (77.3 to 99.2) 64.6 (60.5 to 68.5) 9.3 (6.1 to 14) 99.7 (98.4 to 100)
IBD defined by 
Read code only
5970 148 2266 6 3550 96.1 (91.8 to 98.2) 61 (59.8 to 62.3) 6.1 (5.2 to 7.2) 99.8 (99.6 to 99.9)
Referred only‡ 
(within 6 weeks)
3078 138 1330 11 1599 92.6 (87.3 to 95.8) 54.6 (52.8 to 56.4) 9.4 (8 to 11) 99.3 (98.8 to 99.6)
*With a record of an upper reference range of 50 or above.
†Patients <50 years and abdominal symptoms for >6 weeks.
‡Assumption that referred patients have high probability of disease verification by colonoscopy.
FC, faecal calprotectin; FN, false negatives; FP, false positives; IBD, inflammatory bowel disease; N, sample size; NPV, negative predictive 
value; PPV, positive predictive value; TN, true negatives; TP, true positives.
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in clinical practice if the group represents alternative 
inflammatory conditions that warrant further assess-
ment. However, a broader disease category in primary 
care including other organic conditions in addition to 
IBD resulted in sensitivity estimates ranging from 64% 
to 94%.22–24 As the conditions may follow different path-
ways, interpretation of a test positive result would still be 
challenging. Restricting the group without IBD to those 
with a confirmed IBS record increased the specificity 
by 11 percentage points but has little meaning for clin-
ical practice because it is an artificial patient population. 
Extending the follow- up time to allow for late record-
ings of IBD had no impact on sensitivity and specificity. 
The ROC analysis revealed that the recommended FC 
threshold of 50 µg/g prioritises sensitivity over specificity.
Changing the threshold from 50 to 100 µg/g had a 
greater effect on the specificity than the sensitivity. For 
clinical practice, this could translate into fewer referrals 
of non- IBD patients to gastroenterology at the expense of 
missing an additional nearly 7% of IBD cases. This inter-
pretation is purely based on the logic of test results. Inves-
tigation of the proportion of referrals of patients with true 
positive, false positive, false negative and true negative 
test results showed that the actual management of tested 
patients may not clearly follow the expected behaviour of 
referring positives and managing test negative patients.
This interpretation assumes that referrals were recorded 
consistently for those with and without an IBD record and 
irrespective of FC test outcome. We interpret the findings 
with caution because we could not confirm the final clas-
sification of more than half of the tested patients and 
missing IBD cases cannot be excluded. Furthermore, all 
patients with IBD would have been eventually referred 
according to the definition of an IBD diagnosis, which 
assumed that IBD diagnoses are only recorded following 
confirmation by a gastroenterologist and invasive testing. 
Further, 61 out of 210 (29.0%) IBD cases were either 
referred after 6 weeks or their referral was not recorded.
Strengths and limitations
One benefit of using routine data to estimate a test’s 
accuracy is that the sample size is likely to be larger than 
the usual cross- sectional studies used to evaluate a test. 
This is particularly useful for target disorders such as IBD 
which have a low prevalence.25 We applied strict eligibility 
criteria to ensure the reliability of reported test accu-
racy measures and we explored the effects of different 
follow- up times on the definition of IBD. In the case of FC 
testing in routine primary care, where it is not feasible to 
expose all tested patients to colonoscopy for disease verifi-
cation, we were able to provide an answer to the question 
of the accuracy of the FC test as it is used in UK general 
practice. Our study shows that FC testing together with 
the GP’s decision- making is an effective tool to exclude 
IBD in test negative patients.
The study may have suffered from selection bias 
because the inclusion criterion was a recorded FC test 
rather than symptomatic patients.26 However, we believe 
this to be minimal when considering the point estimates 
and CIs of test accuracy measures in the sensitivity anal-
ysis of patients with eligible symptoms.
The exclusion of close to half of the FC tests without a 
numerical test result raises concerns over the generalis-
ability of the findings because excluded tests were statis-
tically different from the included tests in some variables 
tested. However, the tests were highly powered because 
of the large dataset and the clinical significance of the 
differences is highly uncertain.
Although imputation methods are often used to miti-
gate against missing data, these were not implemented 
for three reasons. First, in observational data, observed 
variables are not sufficient to account for the differences 
between missing and observed values.27 Second, for 
imputation methods to be meaningful, the proportion of 
missing data should be small and the missing subpopula-
tion should be sufficiently similar to the wider population 
neither of which could be confirmed. Third, in order to 
build reliable imputation models, more meaningful vari-
ables are needed including severity of symptoms, assay 
type, referral to gastroenterology and information on 
disease verification method, none of which is available in 
the IMRD- UK database. Therefore, potential biases could 
only be addressed by sensitivity analyses.27
The proportion of patients without a diagnosis following 
testing was large and could be due to any of the following: 
missed IBD, unrecorded IBS, other conditions not consid-
ered as study variables, or diagnoses recorded as free text 
and thus not available to the study. Also the research liter-
ature was too heterogeneous to be able to estimate the 
prevalence of other conditions accurately. For example, 
across five studies,28–32 the number of conditions varied 
widely and the prevalence ranged from 4% (16/399)28 to 
61% (422/694).31 We were unable to predict IBD using 
other variables, such as symptoms and comorbidities, in 
the non- IBD group due to the lack of strong predictors 
of IBD among the study variables. Without any further 
Table 4 Proportion of patients referred by test result and 
disease status
TP FP FN TN Total
Classification of 
included patients 
in primary analysis 
based on FC test 
result, n
195 2219 15 3541 5970
Classification of FC 
tested patients with 
referral based on FC 
test result, n
138 1330 11 1599 3078
Proportion of 
patients in primary 
analysis referred, %
70.8 59.9 73.3 45.3 51.6
FC, faecal calprotectin; FN, false negative; FP, false positive; TN, 
true negative; TP, true positive.
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information on the characteristics of the non- IBD cases, 
their true disease status remains uncertain.
Colonoscopy with histology is the preferred reference 
standard for diagnosis of IBD. However, information on 
secondary care events is not fully captured in the IMRD- 
UK. In the absence of sufficient information on colonos-
copies, we used a combination of Read and drug codes 
as a reference standard under the assumption that IBD is 
not generally coded without confirmatory colonoscopy. 
Our pragmatic study for test accuracy aimed to establish 
the test performance of FC testing as it is used in clinical 
practice. The ideal reference standard is generally not 
feasible in these studies. While this does not invalidate 
the study, the study aim and the performance of the refer-
ence standard need to be considered in the interpreta-
tion of the study findings.
We were interested in the broad category of IBD. While 
ulcerative colitis and Crohn’s disease are the two predom-
inant diagnoses included as part of IBD, they are consid-
ered as the two extremes of a spectrum of chronic gut 
disorders.33–35 IBD cannot be classified in 20%–30% of 
patients at first presentation, resulting in IBD unclassified 
cases.33 34 We also included unclassified forms of IBD such 
as indeterminate colitis and microscopic colitis to present 
the complete picture of IBD in primary care.
Our results are broadly in line with pooled estimates 
from a meta- analysis of 14 secondary and primary are 
studies,11 which may suggest that the pooled test accu-
racy measures are applicable to the FC tested popula-
tion in primary care. At the thresholds investigated, our 
sensitivity and specificity estimates are within the range 
of estimates from published primary care studies.28 36 37 
However, previous primary care studies included small 
numbers of cases, while our study provides narrower CIs 
around test accuracy estimates. Crucially, our study shows 
that the specificity of 94% (95% CI 73% to 99%) reported 
in NICE guidance is not applicable to the primary care 
setting,8 where the broader definition of the non- IBD 
group means that the specificity and the PPV of FC 
testing is much lower. Therefore, the interpretation of a 
test positive result may be challenging. Furthermore, the 
higher number of patients with a false positive result may 
not achieve the reduction of referrals to colonoscopy as 
anticipated by NICE guidance.
Implications for clinical practice
This study indicates that FC testing, when used by GPs, 
does not miss many cases of IBD in a low prevalence 
setting (NPV 99.6% (95% CI 99.3% to 99.7%)). GPs could, 
therefore, use the test confidently in ruling out IBD if the 
test is negative. However, the test does not perform as well 
in identifying IBD as modelled by the national guidance. 
The PPV of the FC test in identifying IBD is low, as essen-
tially FC is a marker of intestinal inflammation rather 
than a specific marker for IBD.
The data also suggested that the higher threshold of 
100 µg/g may be appropriate for routine primary care. 
This is under the understanding that the test is not used 
in isolation and the objective is to reduce the number 
of unnecessary colonoscopies. Patients with missed IBD 
would be assumed to represent and be reconsidered 
for referral within an appropriate time frame. However, 
the latest FC pathway recommends two cut- offs (100 
and 250 µg/g)10 14 with an intermediate test range for 
retesting. The additional IBD cases missed at initial 
testing with this strategy may be inappropriately high. In 
this study, we have not considered the feasibility of this 
latest pathway but it is likely to be more difficult to inter-
pret for GPs.
Our study identified a number of inconsistencies 
between the intended use by the national guidelines and 
the actual use by GPs. First, GPs tested an unexpectedly 
high proportion of patients with IBS, which may suggest 
that GPs use the test to reassure patients with IBS. Second, 
practitioners referred proportionately more patients with 
false negative results than false positive and true negative 
results. This suggests that practitioners use other cues 
for referral rather than test results alone. Third, close 
to half of all negative FC tested patients were referred, 
which suggests that GPs and/or patients may have limited 
confidence in the test. The current guidelines may not 
be applicable to general practice and the modelled cost- 
effectiveness of FC testing in general practice may be 
overoptimistic. When developing national guidance, 
models should more closely represent general practice, 
rather than simply extrapolating from secondary care. 
This study shows for the first time the benefits and short-
comings of the performance of FC testing in a large 
dataset of primary care patients. It should help improve 
GPs’ confidence in their diagnostic ability in this area and 
in test use and interpretation, especially where there is a 
negative test.
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